x
Filter:
Filters applied
- Special Collection: Molecular Imaging
- MicrobubbleRemove Microbubble filter
- 2017 - 2022Remove 2017 - 2022 filter
Special Collection: Molecular Imaging
2 Results
- Original Contribution
Development of a Translatable Ultrasound Molecular Imaging Agent for Inflammation
Ultrasound in Medicine and BiologyVol. 46Issue 3p690–702Published online: December 30, 2019- Alice Luong
- Dan Smith
- Chia-Hung Tai
- Bruno Cotter
- Colin Luo
- Monet Strachan
- and others
Cited in Scopus: 4This study details the development, characterization and non-clinical efficacy of an ultrasound molecular imaging agent intended for molecular imaging of P-selectin in humans. A targeting ligand based on a recently discovered human selectin ligand was manufactured as fusion protein, and activity for human and mouse P- and E-selectin was evaluated by functional immunoassay. The targeting ligand was covalently conjugated to a lipophilic anchor inserted into a phospholipid microbubble shell. Three lots of the targeted microbubble drug product, TS-07-009, were produced, and assays for size distribution, zeta potential and morphology were established. - Original Contribution
Surface Modification with Lactadherin Augments the Attachment of Sonazoid Microbubbles to Glycoprotein IIb/IIIa
Ultrasound in Medicine and BiologyVol. 45Issue 6p1455–1465Published online: March 8, 2019- Kentaro Otani
- Atsunori Kamiya
- Takahiro Miyazaki
- Ayumi Koga
- Ayako Inatomi
- Mariko Harada-Shiba
Cited in Scopus: 5Arginine–glycine–aspartate (RGD)-carrying microbubbles (MBs) have been utilized as a specific contrast agent for glycoprotein IIb/IIIa (αIIbβ3 integrin)-expressing activated platelets in ultrasound molecular imaging. Recently, we found that surface modification with lactadherin provides the RGD motif on the surface of phosphatidylserine-containing clinically available MBs, Sonazoid. Here, we examined the potential of lactadherin-bearing Sonazoid MBs to be targeted MBs for glycoprotein IIb/IIIa using the custom-designed in vitro settings with recombinant αIIbβ3 integrin, activated platelets or erythrocyte-rich human clots.